SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics, Inc. To Present At The 26th Annual ROTH Conference
March 10, 2014
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2013 Financial Results And Business Update
March 6, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
February 10, 2014
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 32nd Annual J.P. Morgan Healthcare Conference
January 14, 2014
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Announces Presentation Of Encouraging Clinical Activity Of TGR-1202 In An Ongoing Multi-Center Phase I Clinical Study
December 9, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Poster Presentations For TGR-1202 At The Upcoming 55th American Society of Hematology Meeting
December 6, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Launches Combination Clinical Trial Of TG-1101 And Ibrutinib In Patients With Select B-Cell Malignancies
December 6, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. To Present At The 2013 Deutsche Bank Biofest Conference
November 26, 2013
 · 
1 min read
Drug Development
TG Therapeutics, Inc. Initiates First Combination Clinical Trial Of TG-1101 And TGR-1202 In Patients With Relapsed And/Or Refractory CLL And NHL
November 25, 2013
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Third Quarter 2013 Financial Results And Business Update
November 12, 2013
 · 
1 min read
Business
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2013 Financial Results and Business Update
November 8, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Comments on Unusual Trading Activity
October 29, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. to Present at BioCentury’s NewsMakers in the Biotech Industry Conference
September 25, 2013
 · 
1 min read
Policy
TG Therapeutics, Inc.’ Ublituximab (TG-1101) Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma (Mucosa-Associated Lymphatic Tissue, MALT)
September 9, 2013
 · 
1 min read
Pharm Country
TG Therapeutics, Inc. Announces Pre-Clinical Poster Presentation for TGR-1202 at the 15th International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Cologne, Germany
September 9, 2013
 · 
1 min read
Business
TG Therapeutics, Inc. Announces Second Quarter 2013 Financial Results and Business Update
August 2, 2013
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS